Returning investor GV took part in a Wellington Management-led series B round that will support assessment of its lead oncology drug candidate.

The genetic testing service, spun out from City University of Hong Kong, took its total funding to approximately $53m with a round co-led by Alibaba and Beyond Ventures.

The Johns Hopkins spinout has passed a clinical milestone to trigger the final part of a series B round backed by Osage University Partners.

Stanford spinout Forty Seven is working on an immuno-oncology treatment to fight the overproduction of proteins which inhibit the immune response to cancer.

The equity investment is part of a cancer vaccine development deal between the companies that could eventually reach more than $1.7bn in size.

The cash will allow Aventamed to seek regulatory approvals to sell its Solo earplant device in the US, having already launched in European markets.

The fibrosis drug developer has passed a clinical milestone to trigger the final part of a series B round backed by Pfizer, Novartis and Bristol-Myers Squibb.

The genetic testing service took its total funding to about $53m with a round co-led by Alibaba Entrepreneurs Fund and VC fund Beyond Ventures.

The firm, launched with a $100m investment by Illumina in April 2016, has added $130m from unnamed external investors.